OT mobile menu

Search form


Genitourinary Cancer Targets

Researchers Identify Genetic Mutation Associated With Poor Outcomes in Prostate Cancer

Inheritance of the HSD3B1 (1245C) allele that enhances dihydrotestosterone synthesis appears to be associated with prostate cancer resistance to ADT. Image © Gam1983/ Shutterstock.com.

Genitourinary Cancer Targets

RNA splicing variants were found to be critical drivers of prostate cancer aggressiveness and therapeutic resistance in African American men.

Men with prostate cancer and one additional primary cancer may harbor a mutation in a cancer-predisposing gene, but the majority of these men do not meet criteria for clinical genetic testing.

A prospective phase III validation study found that AZGP1 has significant prognostic utility as a biomarker in localized prostate cancer.

A study may be able to identify which men with aggressive prostate cancer will benefit from androgen deprivation therapy.

In this video, David Goodrich, PhD, of Roswell Park Cancer Institute in Buffalo, discusses treatment resistance and disease relapse in prostate cancer.

Dr. Roland Seiler presented an analysis of how different bladder cancer molecular subtypes respond to neoadjuvant chemotherapy at the 2017 ASCO Genitourinary Cancer Symposium.

Ahead of the ASCO-sponsored 2017 Genitourinary Cancers Symposium being held February 16th to February 18th in Orlando, Florida, we spoke with Dr. Ana Aparicio about the role of androgen receptors in prostate cancer.


Subscribe to Genitourinary Cancer Targets on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.